دورية أكاديمية
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy
| العنوان: | Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy |
|---|---|
| المؤلفون: | Ciardiello D., Famiglietti V., Napolitano S., Esposito L., Normanno N., Avallone A., Latiano T., Maiello E., Pietrantonio F., Cremolini C., Santabarbara G., Pinto C., Troiani T., Martinelli E., Ciardiello F., Martini G. |
| المساهمون: | Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T., Maiello, E., Pietrantonio, F., Cremolini, C., Santabarbara, G., Pinto, C., Troiani, T., Martinelli, E., Ciardiello, F., Martini, G. |
| سنة النشر: | 2021 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| مصطلحات موضوعية: | Immunotherapy, MCRC, Rechallenge anti‐EGFR, Skin toxicity |
| الوصف: | The single‐arm phase II CAVE mCRC trial evaluated the combination of cetuximab plus avelumab as rechallenge strategy in RAS wild‐type (WT) metastatic colorectal cancer (mCRC) patients, with clinical response to first‐line anti‐EGFR‐based chemotherapy, who progressed and received a subsequent line of therapy. The correlation of skin toxicity (ST) and different clinicomolecular variables with overall survival (OS), progression‐free survival (PFS) and response rate (RR) was assessed at univariate and multivariate analysis. A total of 33/77 (42.9%) patients experienced grade 2–3 ST and displayed median OS (mOS) of 17.8 months (CI 95%, 14.9–20.6); whereas 44/77 (57.1%) patients with grade 0–1 ST exhibited mOS of 8.2 months (CI 95%, 5.5–10.9), (hazard ratio (HR), 0.51; CI 95%, 0.29–0.89; p = 0.019). Median PFS (mPFS) was 4.6 months (CI 95%, 3.4–5.7) in patients with grade 2–3 ST, compared to patients with grade 0–1 ST with mPFS of 3.4 months (CI 95%, 2.7–4.1; HR, 0.49; CI 95%, 0.3–0.8; p = 0.004). Grade 2–3 ST (HR, 0.51; CI 95%, 0.29– 0.89; p = 0.019) and RAS/BRAF/EGFR WT circulating tumor DNA (ctDNA) (HR, 0.50; CI 95%, 0.27– 0.9; p = 0.019) had a statistically significant effect on OS at univariate analysis. At the multivariate analysis, RAS/BRAF/EGFR WT ctDNA status maintained statistical significance (HR, 0.49; CI 95%, 0.27–0.9; p = 0.023), whereas there was a trend towards ST grade 2–3 (HR, 0.54; CI 95%, 0.29–1.01; p = 0.054). Skin toxicity is a promising biomarker to identify patients with mCRC that could benefit of anti‐EGFR rechallenge. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34830870; info:eu-repo/semantics/altIdentifier/wos/WOS:000723622100001; volume:13; issue:22; numberofpages:12; journal:CANCERS; https://hdl.handle.net/11568/1113672Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118929902; https://www.mdpi.com/2072-6694/13/22/5715Test |
| DOI: | 10.3390/cancers13225715 |
| الإتاحة: | https://doi.org/10.3390/cancers13225715Test https://hdl.handle.net/11568/1113672Test https://www.mdpi.com/2072-6694/13/22/5715Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.7E1DE82A |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers13225715 |
|---|